Differentiating CD8αβ T Cells from TCR-Transduced iPSCs for Cancer Immunotherapy
Differentiating CD8αβ T Cells from TCR-Transduced iPSCs for Cancer Immunotherapy
复制标题
将 CD8αβ T 细胞与 TCR 转导的 iPSC 区分开来进行癌症免疫治疗
DOI：
10.1007/978-1-4939-9728-2_9
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Kaneko Shin
中科院分区：
文献类型：
--
作者：
Minagawa Atsutaka;Kaneko Shin
使用诱导多能干细胞(IPSCs)作为产生细胞毒性T淋巴细胞(CTL)的细胞来源有望在抗原特异性、返老性和可重复性方面具有优势。我们已经开发了一种从TcR转导的IPSCs(TCRIPSCs)中区分CD8IPSCs的方法(αβ-IPSCs)。这些T细胞表达转导TCR的单克隆性表达。从TCRIPSC中产生CD8CTL有助于安全有效的同种异体再生性T细胞免疫治疗。
The use of induced pluripotent stem cells (iPSCs) as a cell source for producing cytotoxic T lymphocytes (CTLs) is expected to have advantages in the antigen specificity, rejuvenation profile, and reproducible number of CTLs. We have developed the way to differentiate CD8αβ T cells from TCR-transduced iPSCs (TCR-iPSCs). These T cells express monoclonal expression of the transduced TCR. Generating CD8αβ CTLs from TCR-iPSC could contribute to safe and effective allogeneic regenerative T cell immunotherapies.